To the Editor,

Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase indicated for chronic lymphocytic leukaemia (CLL) treatment \[[@CR1]\]. Most common side effects are bleeding and ibrutinib-related atrial fibrillation (IRAF) \[[@CR2], [@CR3]\]. IRAF pathogenesis is still unclear, and a direct drug effect on myocardiocyte signalling has been postulated \[[@CR4]\]. Various *real-life* cohorts have been retrospectively reported, focusing on ibrutinib-related adverse event management \[[@CR5], [@CR6]\]. A retrospective study on a large population of CLL patients revealed an association of AF risk with older age, male sex, valvular heart disease, and hypertension \[[@CR7]\]. However, no prospective ad hoc studies are available. We systematically analysed predictors of IRAF in 43 CLL patients treated with ibrutinib, focusing on comorbidities, electrocardiographic features (12-derivation electrocardiography (ECG), 24-h ECG monitoring in selected case), and trans-thoracic echocardiography (TTE). Framingham Heart Study and Shanafelt risk score for AF were also calculated for each patient (Additional file [1](#MOESM1){ref-type="media"}: Supplementary material) \[[@CR7], [@CR8]\].

Patients' clinical and biological characteristics together with baseline cardiologic comorbidities are presented in Table [1](#Tab1){ref-type="table"} (Additional file [1](#MOESM1){ref-type="media"}: Supplementary results). Previous paroxysmal AF was reported in 5 patients, but in none of them was detectable at the time of cardiologic evaluation nor in the previous 6 months. AF-risk score individuated 8 patients at low, 18 at intermediate low, 6 at intermediate high, and 11 at high risk. Twenty-three patients were taking cardio-active therapy, 13 were under antiplatelets, and 4 under anticoagulant therapy at the time of enrolment. ECG and ECG-Holter analysis did not display any remarkable alterations (Additional file [1](#MOESM1){ref-type="media"}: Table S1). TTE demonstrated left atrial (LA) diameter and area over the 75° percentile in 16 and 30% of patients, respectively, although with preserved function. Median observation period was of 8 months (range 1--37). AF occurred in 7 patients (16.3%) after a median of 6 months (range 1--20) from the beginning of ibrutinib. In 5 patients (71%), IRAF developed within 6 months, whereas it occurred within the first year in the other two. AF severity was G2 in 4 patients, G3 in 2, and G1 in 1 only. IRAF cases were all elderly pre-treated males in advanced stage, and one of them had previous history of AF and 6 (85.7%) had arterial hypertension. IRAF incidence significantly correlated with male gender (*p* = 0.04) and history of arterial hypertension (*p* = 0.009). On the whole, IRAF occurred in 25% of the 28 patients with one or more pre-existent cardiologic comorbidities, whereas incidence was 0 in those without (*N* = 15, *p* = 0.03; Additional file [1](#MOESM1){ref-type="media"}: Table S2). Of note, a high AF-risk score was detected in 86% of patients who developed IRAF versus 14% in those who did not (*p* \< 0.001, Fig. [1](#Fig1){ref-type="fig"}, upper panel). No correlation was found with basal ECG evaluation, whereas TTE data showed a significant association with IRAF incidence; IRAF cases displayed higher LA diameter (*p* = 0.02) and area (*p* = 0.03; Fig. [1](#Fig1){ref-type="fig"}, lower panel) compared to the others. The occurrence of AF was managed with anticoagulation in four (57.1%) patients, and anti-arrhythmic drugs in five (71.4%). Only one patient underwent electric cardioversion. As regards new onset of arterial hypertension, we observed four events (3 grade III, 1 grade II) after a median of 4.8 months (range 1--27). All four cases were managed with therapy modification, without ibrutinib discontinuation.Table 1Baseline characteristics*N* (%)Age years72 (51--86)GenderF14 (32) M29 (68)Follow-up months8 (1--37)STAGERai I/II23 (53)Rai III/IV20 (47)Binet A/B26 (60)Binet C17 (40)FISHdel1313 (30)trisomy 123 (7)del17p or TP53 mut12 (28)del11q5 (12)VHIGMutated10/36 (28)Unmutated26/36 (72)TreatmentFirst-line12 (28)≥Second line31 (72)Cardiovascular comorbiditiesPrevious AF5 (12)AH23 (53)Valvular heart disease20 (47)CAD8 (19)PAD4 (9)Diabetes4 (9)Hypothyroidism5 (12)Dislipidaemia12 (28)Smoke1 (2)BMI \> 257 (16)Values are given as median (range) or as *N* (%). *AH* arterial hypertension, *CAD* coronary artery disease, *PAD* peripheral artery disease, *BMI* body mass indexFig. 1Upper panel: AF risk score according to IRAF incidence. AF risk score was calculated on age, gender, arterial hypertension, and valvular heart disease (Shanafelt et al.). Percentages of patients developing or not developing IRAF are shown divided into four risk categories. IRAF cases were mainly in the high risk group (≥ 5 RF), *p* \< 0.001. *AF* atrial fibrillation. *IRAF* ibrutinib-related atrial fibrillation. *RF* risk factors. Lower panel: main echocardiographic characteristics associated with IRAF. LA diameter, area, and volume were increased in IRAF patients compared to the others, significantly for the former two parameters (*p* = 0.02 and *p* = 0.03, respectively). *LA* left atrium, *IRAF* ibrutinib-related atrial fibrillation

In this prospective analysis, we firstly show that baseline echocardiographic characteristics significantly predict IRAF occurrence. We describe a higher incidence of IRAF compared to previous reports, possibly due to closer cardiologic evaluation. Accordingly, methods for IRAF screening were not detailed in previous studies, with possible underestimation \[[@CR8]\]. In the Shanafelt series, only 72 out of 2444 patients were treated with ibrutinib and only 2 of them developed IRAF. As a matter of fact, this score is more predictive of AF in CLL general population than of IRAF. However, Shanafelt risk score significantly predicted IRAF development in our study, indicating high reproducibility. As regards echocardiography, in our series, TTE-measured LA linear dimensions and area clearly correlated with higher IRAF incidence, pointing out that it may be a useful and non-invasive tool to assess IRAF risk in ibrutinib candidates. Finally, similarly to previous experiences, only half of IRAF cases received anticoagulation because of both high bleeding risk and possible drug interactions \[[@CR5], [@CR7], [@CR9]\]. In conclusion, TTE is a highly reproducible, widespread, and low-cost procedure that might be easily included in the pre-treatment workup of ibrutinib candidates, and self-interpreted by a skilled haematologist.
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